Radar · Oncology in Boston
Best Oncology Companies in Boston, United States
The 84 best Oncology companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Fog Pharmaceuticals.
By Rohit KhannaTrends & Stories
84companies tracked
$4.1Bdisclosed funding
0unicorns
60have raised
FLIAR INTELLIGENCE · ONCOLOGY × BOSTON
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
146kcombined LinkedIn audience
30%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Boston
| # | Company | Disclosed funding | Last round | Employees | Founded | Stage | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Fog Pharmaceuticals Developer of cell-penetrating mini-proteins to target intracellular disease drivers | $531M | 27 mo ago | 97 97 → 197 (+103%) · sector median +43% | 2015 | Series E | — | — | 1 partnership |
| 2 | Scorpion Developer of drugs for the treatment of cancer | $420M | 13 mo ago | 62 | 2020 | Series C | — | — | — |
| 3 | Aktis Oncology Developer of radiopharmaceuticals for solid tumor cancers | $336M | 21 mo ago | 15 | 2021 | Public | — | 26 patents Targeted cancer therapeutics using engineered miniprotein ligands and conjugates | — |
| 4 | Alpha-9 Oncology Developer of radiopharmaceuticals for the treatment of cancer | $261M | 19 mo ago | — | 2018 | Series C | David Hirsch CEO | — | — |
| 5 | CervoMed Developer of therapeutics for neurodegenerative diseases | $209M | 15 mo ago | 13 13 → 20 (+54%) · sector median +43% | 2001 | Public | John Alam Co-Founder & CEO | — | — |
| 6 | Pyxis Oncology Developer of antibody therapeutics for treating cancer | $194M | 27 mo ago | 50 50 → 68 (+36%) · sector median +43% | 2019 | Public | Thomas Gajewski Co-Founder | 10 patents Targeted antibody‑drug conjugates against KLRC1, GPNMB, and fibronectin‑EDB cancer biomarkers. | — |
| 7 | TScan Therapeutics Developer of T cell therapies to harness the immune system against cancer | $180M | 64 mo ago | 154 154 → 151 (-2%) · sector median +43% | 1995 | Public | — | 162 patents Targeted binding protein therapeutics for cancer immunotherapy and hematologic malignancies | 1 launch · 1 partnership |
| 8 | SQZBiotech Developer of cell therapies to treat multiple diseases | $168M | 51 mo ago | 117 | 2013 | Acquired | — | — | — |
| 9 | Ikena Oncology Developer of biomarker-based therapies for treating cancer | $168M | 34 mo ago | 80 | 2016 | Public | George Georgiou Co-Founder & Director | 201 patents Small-molecule cancer drugs targeting AHR modulation and MEK inhibition | — |
| 10 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | 2022 | Series A | Sanjaya Singh Founder & Chief Scientific Officer | — | — |
| 11 | Acetylon Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $138M | 154 mo ago | 37 | 2008 | Acqui-Hired | Marc Cohen Co-Founder | — | — |
| 12 | Exosome Diagnostics Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring | $119M | 107 mo ago | 51 | 2008 | Acquired | — | 230 patents Exosome-based biomarker detection for cancer, autoimmune diseases, and liquid biopsy diagnostics | — |
| 13 | Aprea Developer of small molecule therapeutics targeting tumor suppressor proteins 40Funding top 18%Growth top 30%News top 38%Moat top 48% All 7 signals ▾Fundingtop 18% Growthtop 30% Newstop 38% Moattop 48% Globalbottom 42% Techbottom 35% Marketbottom 25% Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $113M | 6 mo ago | 13 | 2003 | Public | — | — | — |
| 14 | Tokai Pharmaceuticals Specialty company developing therapies for patients with prostate cancer and hormonally-driven diseases | $100M | 157 mo ago | 17 | 2004 | Acquired | — | — | — |
| 15 | RatioTX Developer of targeted radiotherapeutics for the treatment of cancers | $90M | 30 mo ago | 31 | 2021 | Series B | John Babich Co-Founder | — | 3 partnerships |
| 16 | Regor Provider of therapeutics related to oncology, autoimmune and metabolic disease | $90M | 64 mo ago | 36 | 2018 | Acquired | — | — | — |
| 17 | Orionis Biosciences Developer of precision medicines to treat cancer and other diseases | $79M | 44 mo ago | 47 47 → 62 (+32%) · sector median +43% | 2015 | Series C | Nikolai Kley CEO & President | 209 patents Engineered protein biologics for targeted immunotherapy and fibroblast modulation | 1 partnership |
| 18 | ENSEM Developer of transformative therapies for the treatment of cancer | $67M | 50 mo ago | 34 | 2021 | Series A | — | — | — |
| 19 | Normunity Developer of immunotherapies for the treatment of cancer | $65M | 17 mo ago | 19 | 2020 | Series B | Lieping Chen Co-Founder | 4 patents Therapeutic antibodies targeting KLK6, LY6K, and PLA2G10 for disease treatment | — |
| 20 | Incendia Therapeutics Developer of immunotherapy for cancer treatment | $65M | 55 mo ago | 21 | 2019 | Series A | Guy Clifton Co-Founder | — | — |
| 21 | Precede Developer of liquid biopsy platform providing disease-defining biology from blood tests | $57M | 32 mo ago | — | 2021 | Series C | Rehan Verjee Co-Founder & CEO | — | 1 award |
| 22 | Maverick Therapeutics Developer of T-cell-based antibody therapies for the treatment of cancer | $56M | 113 mo ago | 32 | 2014 | Acquired | — | — | — |
| 23 | Kelonia Developer of medicines to treat autoimmune and inflammatory conditions | $50M | 49 mo ago | 45 | 2021 | Acquired | — | — | — |
| 24 | Ankyra Developer of immunotherapies for the treatment of cancer | $45M | 55 mo ago | 10 | 2019 | Series B | Darrell Irvine Co-Founder | — | — |
| 25 | Abpro Developer of antibody therapies for cancer and infectious diseases | $42M | 50 mo ago | 24 24 → 36 (+50%) · sector median +43% | 2007 | Public | Ian Chan Co-Founder & CEO | 28 patents Multispecific therapeutic antibodies for cancer and eye disease targeting VEGF, ANG2, HER2, CD3, claudin‑18.2 | — |
| 26 | Solu Therapeutics Developer of therapeutics for oncology and immunology diseases | $31M | 14 mo ago | 9 | 2022 | Series A | John Pribis Co-founder | — | — |
| 27 | AOA Provider of an AI-enabled early detection platform focused on womens health 45Funding top 24%Patents top 27%Talent top 28%Innovation top 33% All 8 signals ▾Fundingtop 24% Patentstop 27% Talenttop 28% Innovationtop 33% Moattop 47% Globalbottom 44% Marketbottom 21% Newsbottom 18% Funding: Raised $30.7M across 7 rounds · 7 rounds over 5 yrs (1.4/yr) Patents: 22 patents matched (strict assignee match) · 21 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $31M | 8 mo ago | 3 | 2019 | Series A | Alex Fisher Co-Founder & COO | 22 patents Cancer diagnostic biomarkers and mass‑spectrometry methods for tumor detection | 1 award |
| 28 | hC Bioscience Developer of RNA-based therapeutics to treat cancer and rare diseases | $24M | 54 mo ago | 31 | 2021 | Series B | Leslie Williams Co-Founder & CEO | 102 patents Patents concentrated in health & consumer products | — |
| 29 | Alloplex Biotherapeutics Developer of anti-tumor vaccine | $22M | 40 mo ago | 6 | 2016 | Series A | Frank Borriello Founder & CEO | 33 patents Allogeneic tumor cell vaccines and T‑cell expansion for cancer immunotherapy | — |
| 30 | Monopteros Therapeutics Developer of immunotherapies for cancer treatment | $20M | 62 mo ago | — | 2019 | Deadpooled | Peter Keller CEO | — | — |
| 31 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | 2016 | Series B | Rodrigo Navarro Co-Founder & CEO & President | 45 patents Nanostructured drug delivery systems and malaria transmission-blocking vaccine technologies. | — |
| 32 | Aphios Developer of therapeutic products and enabling technology platforms for healthcare | $17M | 20 mo ago | 12 | 1993 | Funding Raised | — | 81 patents Pathogen inactivation in blood products and nanotech drug delivery for cannabinoids | — |
| 33 | JURA Bio Developer of cell therapies for immunological disorders | $16M | 33 mo ago | 7 | 2017 | Series B | George Church Co-Founder | — | — |
| 34 | Transcode Therapeutics Developer of mRNA therapeutics to treat cancer | $13M | 18 mo ago | 19 19 → 16 (-16%) · sector median +43% | 2015 | Public | — | — | — |
| 35 | CoStim Pharmaceuticals Urban regeneration development company creating sustainable value through innovative real estate projects | $10M | 158 mo ago | 90 | 2012 | Acquired | — | — | — |
| 36 | Boston Immune Technologies & Therapeutics Developer of immune-based therapies for treating cancer and infectious diseases | $10M | 16 mo ago | 6 | 2011 | Series A | — | — | — |
| 37 | Window Therapeutics Developer of therapeutics for cancer treatment | $8M | 32 mo ago | 6 | 2021 | Series A | — | — | — |
| 38 | CureLab Developer of immunostimulants and vaccines against cancer | $7M | 220 mo ago | 10 | 2002 | Funding Raised | — | 8 patents Designing engineered nucleic acid sequences for vaccine and therapeutic applications | — |
| 39 | Xios Therapeutics Immune-targeted small molecule therapies for cancer | $7M | 95 mo ago | 1 | 2015 | Deadpooled | Diala Ezzeddine President & CEO | — | — |
| 40 | Inform Genomics Provider of pharmacogenomics tools for cancer | $6M | 125 mo ago | 1 | 2010 | Seed | — | — | — |
| 41 | Predicta Biosciences Provider of diagnostic and therapeutic products for oncology | $5M | 8 mo ago | — | 2023 | Series A | Gad Getz Co-Founder | — | 1 partnership · 1 award |
| 42 | Genospace Bridging clinical research and care with data-driven precision medicine | $5M | 140 mo ago | 22 22 → 42 (+91%) · sector median +43% | 2011 | Acquired | — | — | — |
| 43 | Adecto Pharmaceuticals Developing targeted cancer therapies and companion diagnostics for ADAM8-positive tumors | $4M | 45 mo ago | 3 | 2014 | Funding Raised | Gail Sonenshein Founder & President | — | — |
| 44 | Oncovision Provider of diagnostic imaging devices for oncology | $4M | 33 mo ago | 26 | 2003 | Acquired | Noriel Pavon Founder | — | — |
| 45 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 11 mo ago | 9 | 2019 | Series A | Anas Fathallah Co-Founder & CEO | — | — |
| 46 | InnoTech Precision Medicine Developer of multimodal molecular diagnostic platform for early disease detection | $3M | 10 mo ago | 5 | 2021 | Funding Raised | Reza Mollaaghababa Co-Founder | — | 1 internship · 1 launch |
| 47 | Advanced Proteome Therapeutics Technology platform to develop targeted treatment of cancers | $3M | 72 mo ago | 5 | 2005 | Public | Allen Krantz President/CEO | — | — |
| 48 | Boston Biomedical Develops novel therapeutics for treatment of cancer | $2M | 192 mo ago | 30 | 2006 | Acquired | — | 373 patents Small-molecule cancer therapeutics targeting stem cells and epigenetic pathways | — |
| 49 | SIWA Therapeutics Developing a monoclonal antibody that targets and destroys senescent cells. | $2M | 109 mo ago | 9 | 2016 | Seed | Misty Gruber Co-Founder & President | — | — |
| 50 | VaxSyna Developer of vaccine and antibody therapeutics | $437K | 50 mo ago | 4 | 2020 | Funding Raised | Joseph Hunter Co-Chief Executive Officer | — | — |
Top 12 Oncology companies in Boston
#1
Series A · Boston, Massachusetts · founded 2022$165Mraised▾
Series A · Boston, Massachusetts · founded 2022
Developer of therapetics for cancer and immunological diseases. It offers multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. It has technology platform a solid tumor synergy platform and an I&I platform fornimmune regulation at a tissue-specific level.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Moat
bottom 48%Tech
bottom 47%Global
bottom 36%Market
bottom 32%Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers — 2.5% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Adagene) announced in 12 mo
Funding rounds
- Feb 2026Series A$52M
- Jul 2024Series A$165M
Founders & team
Investors
Vida Ventures, Cormorant Asset Management, Hillhouse, Goldman Sachs Asset Management, BVF Partners, Janus Henderson Investors
Tech stack
AosCookieyesCore-JsDocusignGatsbyGodaddy
#2
Public · Boston, Massachusetts · founded 2003 · 13 employees$113.2Mraised▾
Public · Boston, Massachusetts · founded 2003 · 13 employees
Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 18%Growth
top 30%News
top 38%Moat
top 48%Global
bottom 42%Tech
bottom 35%Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Post IPO (Dec 2025)
Growth: Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 31 tracked, 5 types) · +33% YoY · Top themes: Earnings, Announcements, Funding
Funding rounds
- Dec 2025Post IPO$3.1M
- Mar 2024Post IPO—
- Feb 2023Grant (prize money)$2M
- Feb 2019Series C$5.7M
Investors
Nantahala Capital Management, DAFNA Capital Management, Exome Asset Management, Sphera Fund, Stonepine, Janus Henderson Investors
#3
Series B · Boston, Massachusetts · founded 2016 · 10 employees$17.1Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 10 employees
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 31%Funding
top 37%Moat
top 38%Innovation
top 41%Tech
bottom 38%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 · Latest publication 2025
Funding: Raised $17.1M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (May 2026)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. VCTS) announced in 12 mo
Funding rounds
- May 2026Series B—
- May 2023Series B$13M
- Jul 2020Series A$4.1M
Founders & team
Tech stack
AosAzureBootstrapCdnjsCloudflareCookieyes
#4
Series C · Boston, Massachusetts · founded 2020 · 62 employees$420Mraised▾
Series C · Boston, Massachusetts · founded 2020 · 62 employees
Developer of drugs for the treatment of cancer. The company aims to develop next-generation targeted therapy for untreatable/ treatment-resistant cancer.
Funding rounds
- May 2025Series C$30M
- Jul 2024Series C$150M
- Jan 2021Series B$162M
- Oct 2020Series A$108M
Investors
Boxer Capital, EcoR1, Vida Ventures, Omega Funds, Invus, Citadel
#5
Public · Boston, Massachusetts · founded 2001 · 13 employees$208.9Mraised▾
Public · Boston, Massachusetts · founded 2001 · 13 employees
Developer of therapeutics for neurodegenerative diseases. It offers a lead product neflamapimod an oral, selective small molecule inhibitor of the protein kinase p38 alpha for treating dementia with Lewy bodies and Alzheimer’s disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 2.0% of this cohort's audience
Funding rounds
- Mar 2025Grant (prize money)$21.1M
- Mar 2025Grant (prize money)$21.1M
- Mar 2024Post IPO$149.4M
- Feb 2023Grant (prize money)$15M
Founders & team
Investors
HHS, RA Capital Management, Armistice Capital, Soleus Capital, Special Situations Funds
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#6
Series A · Boston, Massachusetts · founded 2019 · 3 employees$30.7Mraised▾
Series A · Boston, Massachusetts · founded 2019 · 3 employees
Provider of an AI-enabled early detection platform focused on womens health. It offers a proprietary multi-omics platform called GlycoLocate to diagnose early-stage cancers by using a non-invasive blood test. and AKRIVIS GD is a liquid biopsy test that uses a multi-omics to analyze tumor-associated lipids and proteins for the diagnosis of ovarian cancer.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 24%Patents
top 27%Talent
top 28%Innovation
top 33%Moat
top 47%Global
bottom 44%Funding: Raised $30.7M across 7 rounds · 7 rounds over 5 yrs (1.4/yr) · Last round Series A (Oct 2025)
Patents: 22 patents matched (strict assignee match) · 21 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers — 8.0% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series A$8.1M
- Dec 2024Seed$1.8M
- Jul 2023Seed$23.6M
- Sep 2022Seed$4.5M
Founders & team
Investors
Massachusetts Life Sciences Center, Joyance Partners, Avestria Ventures, AlleyCorp, Launchpad Venture Group, TBD Angels
#7
Public · Boston, Massachusetts · founded 2021 · 15 employees$336Mraised▾
Public · Boston, Massachusetts · founded 2021 · 15 employees
Developer of radiopharmaceuticals for solid tumor cancers. The company had developed platforms to generate tumor-targeting agents for radiotherapy that are designed for high tumor penetration and long residence time. The therapeutic radioisotope molecules developed eliminates tumors from the body and minimize the side effects.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 13k LinkedIn followers — 9.0% of this cohort's audience
Funding rounds
- Sep 2024Series B$175M
- Aug 2022Series A$84M
- Mar 2021Series A$72M
Investors
EcoR1, Vida Ventures, Novartis, Bristol-Myers Squibb, Octagon Capital Advisors, Cowen
Tech stack
Contact Form 7Core-JsGenesis ThemeGodaddyGoogle AnalyticsGoogle Tag Manager
#8
Series C · Boston, Massachusetts · founded 2018$261Mraised▾
Series C · Boston, Massachusetts · founded 2018
Developer of radiopharmaceuticals for the treatment of cancer. The company applies radiotherapeutic design by a toolbox of technologies for peptide-based radiopharmaceuticals to deliver radiation to cancer cells for the treatment of people living with cancer.
Funding rounds
- Oct 2024Series C$175M
- Dec 2022Series B$75M
- Apr 2021Series A$11M
Founders & team
Investors
Nextech Invest, Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital, BVF Partners
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsDocusignFont Awesome
#9
Series B · Boston, Massachusetts · founded 2020 · 19 employees$65Mraised▾
Series B · Boston, Massachusetts · founded 2020 · 19 employees
Developer of immunotherapies for the treatment of cancer. It is developing a pipeline of immune normalizers to restore the immune system’s intrinsic activity to identify and eliminate cancer cells. The lead program is a monoclonal antibody targeting a secreted enzyme that is highly upregulated in multiple human cancers and drives the exclusion of T-cell infiltration in immuno-sensitive tumors.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Jan 2025Series B$75M
- Oct 2022Series A$65M
Founders & team
Investors
Canaan, Taiho Ventures, Osage University Partners, Sanofi Ventures, Samsara BioCapital, Enavate Sciences
#10
Series A · Boston, Massachusetts · founded 2022 · 9 employees$31Mraised▾
Series A · Boston, Massachusetts · founded 2022 · 9 employees
Developer of therapeutics for oncology and immunology diseases. It offers a cytotoxicity-targeting chimera platform that provides cancer therapeutics and eliminates cells that drive inflammatory and autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 3.2% of this cohort's audience
Funding rounds
- Apr 2025Series A$41M
- Aug 2023Seed$31M
Founders & team
Investors
Longwood Fund, Sante, DCVC, Astellas Venture Management, Alexandria, Lilly
Tech stack
CloudflareCookiebotGoogle AnalyticsHotjarHstsHttp/3
#11
Series E · Boston, Massachusetts · founded 2015 · 97 employees$530.9Mraised▾
Series E · Boston, Massachusetts · founded 2015 · 97 employees
Fog Pharmaceuticals is developing cell-penetrating mini-proteins, molecules that combine the ability of proteins to target large flat surfaces, with the ability of small molecules to penetrate cells.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 19k LinkedIn followers — 13.1% of this cohort's audience · 241 engagements/post (1.9× cohort median)
Hiring: 1 hiring post in 12 mo (public) · hiring: Senior Director, Clinical Pharmacology & Pharmacometrics (CPP)
Activity: 1 partnerships (incl. Regeneron Pharmaceuticals) announced in 12 mo
Funding rounds
- Mar 2024Series E$145M
- Nov 2022Series D$178M
- Mar 2021Series C$107M
- Jan 2021Series B$23.3M
Investors
6 Dimensions Capital, Google Ventures, Blue Pool Capital, Horizons Ventures, SVB Securities, Deerfield
#12
Series A · Boston, Massachusetts · founded 2023$5.2Mraised▾
Series A · Boston, Massachusetts · founded 2023
Provider of diagnostic and therapeutic products for oncology. It offers a non-invasive diagnostics focus on multiple myeloma and evaluate patients’ immune system cells to determine the patient responding to immunotherapies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 2 partnerships · 1 awards (incl. Tempus AI) announced in 12 mo
Funding rounds
- Oct 2025Series A$23.4M
- Jul 2024Seed$5.2M
Founders & team
Investors
Engine Ventures, Illumina Ventures, Time Partners, American Cancer Society - North Carolina, Lightchain Capital, Mass General Brigham
Funding & investor landscape
$4.1Btotal disclosed funding
59companies funded
191disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Sanjaya Singh
Founder & Chief Scientific Officer · Third Arc Bio
Peter Lebowitz
CEO · Third Arc Bio
Rodrigo Navarro
Co-Founder & CEO & President · 4D Path
Supratim Ray
Co-Founder & CIO · 4D Path
John Alam
Co-Founder & CEO · CervoMed
Alex Fisher
Co-Founder & COO · AOA
Anna Jeter
Co-Founder · AOA
David Hirsch
CEO · Alpha-9 Oncology
Lieping Chen
Co-Founder · Normunity
Rachel Humphrey
President and Founding CEO · Normunity
John Pribis
Co-founder · Solu Therapeutics
David Donabedian
Co-founder · Solu Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN BOSTON · Health & Bio
How research on Oncology in Boston is moving
A read on the academic research around Oncology in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 198 papers.
198 papers · stance +0.57 · 40% breakthrough · 9% concern
top institutions
- Boston Children\'s Hospital76
- Boston University68
- Boston Medical Center22
- Dana-Farber/Boston Children\'s Cancer and Blood Disorders Center17
- Boston Engineering14
leading researchers
Andrew Chen · King, Jennifer M. · Lina Kroehling · Meric-Bernstam, Funda · Msaouel, Pavlos · Tannir, Nizar M.
prism intelligence · tone & topics
96% positive · 1% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthHealthcare
▲
Breakthroughs72 · 36%
▲ 36%→37% share
▲1.0× share momentum1 median citations89% since 2021mostly empirical
Breakthroughs are rising (36%→37% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment3→28
- Cancer research5→26
- Immune system2→18
- Immunotherapy1→12
- Cancer1→7
Newly emergingMetastasis 0→7 · Stromal cell 0→6 · Organoid 0→5
Landmark PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity · 865 cites
◆
Advancements91 · 46%
▲ 45%→47% share
▲1.0× share momentum1 median citations91% since 2021mostly empirical
Advancements are rising (45%→47% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment3→40
- Immune system3→27
- Immunotherapy2→21
- Cancer research2→20
- Cytotoxic T cell1→6
Newly emergingTranscriptome 0→11 · Renal cell carcinoma 0→9 · Cancer 0→9
Landmark Tumor microenvironment complexity and therapeutic implications at a glance · 1,729 cites
▼
Concerns17 · 9%
▼ 18%→7% share
▼0.4× share momentum10 median citations82% since 2021mostly reviews
Concerns are cooling (18%→7% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment1→5
- Cancer research1→3
Newly emergingImmunotherapy 0→7 · Immune system 0→6 · Immunology 0→3
Landmark CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy · 603 cites
Common questions
How many Oncology companies are there in Boston, United States?
Radar tracks 84 indexable Oncology companies headquartered in Boston, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Boston, United States?
The Oncology companies in Boston, United States on this list have raised a combined $4.1B in disclosed equity funding across 59 funded companies.
Which is the highest-funded Oncology company in Boston, United States?
Fog Pharmaceuticals is the highest-funded Oncology company in Boston, United States, with $530.9M in disclosed equity funding.
How many Oncology companies in Boston, United States are funded?
59 of the 84 Oncology companies in Boston, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Boston, United States?
None of the Oncology companies in Boston, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Boston, United States Oncology companies?
The most active investors in Boston, United States Oncology companies on this list include HHS, Janus Henderson Investors, RA Capital Management, MassChallenge, BVF Partners.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.